Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019
(COVID-19) because of its involvement in driving cytokine storm. This systematic review and …

Introduction Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts
body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors …

Summary Objectives Multiple RCTs of interleukin-6 (IL-6) inhibitors in COVID-19 have been
published, with conflicting conclusions. We performed a meta-analysis to assess the impact …

Objective To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in
COVID-19 patients. Data Sources A systematic review of the MEDLINE and Scopus …

Purpose COVID-19 is characterized by dysregulated immune response, respiratory failure
and a relevant mortality rate among hospitalized patients. Interleukin-6 (IL-6) is involved in …

The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection has been spreading globally, raising increasing concerns. This public health …

Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …

In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6
(IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed …

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a
dysregulated hyperinflammatory response. Areas covered Authors review evidence on IL-6 …

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid
development of clinical trials targeting this cytokine. Overall, these trials do not support the …